Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
| Autor: | Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., Cameron, D. |
|---|---|
| Zdroj: | In Journal of Bone Oncology November 2018 13:123-135 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|